Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-oesophageal Junction, and Oesophageal Tumours

Trial Profile

Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-oesophageal Junction, and Oesophageal Tumours

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2017 Planned End Date changed from 1 Mar 2018 to 28 Feb 2021.
    • 18 Mar 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov record.
    • 18 Mar 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top